The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction
The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
Aims: The aim of this study was to estimate the cost-effectiveness, from the perspective of the Australian public healthcare system, of icosapent ethyl in combination with statin therapy compared with statin alone for the prevention of cardiovascular disease. Methods and results: A Markov model populated with data from the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial was designed to predict the effectiveness and costs of icosapent ethyl in combination with statins compared with statins alone over a 20-year time horizon. Data inputs for costs and utilities were sourced from published sources. The annual costs of icosapent ethyl were assumed to be AUD1637 (USD2907) per person. All future costs and outcomes were discounted annually by 5%. The main outcome of interest was incremental cost-effectiveness ratios in terms of cost per quality adjusted life year (QALY) gained and per year of life saved (YoLS). Over a 20-year time horizon, compared with statin alone, icosapent ethyl in combination with statin was estimated to cost an additional AUD$13,022 per person, but led to 0.338 YoLS and 0.289 QALYs gained (all discounted). These equated to incremental cost-effectiveness ratios of AUD45,036 per QALY gained and AUD38,480 per YoLS. Sub-analyses for primary and secondary prevention were AUD96,136 and AUD35,935 per QALY gained, respectively. The results were sensitive to time-horizon, age related trends and the acquisition price of icosapent ethyl. Conclusion: Compared with statin alone, icosapent ethyl in combination with statin therapy is likely to be cost-effective in the prevention of cardiovascular disease assuming a willingness-to-pay threshold of AUD50,000 per QALY gained, especially in the secondary preventive setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Consequently, recent economic analyses found icosapent ethyl could be a cost-effective treatment, particularly for secondary cardiovascular prevention, in the USA, Germany, UK, Canada, Australia, and Japan [22, 23, 116–121].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [116]
Citations
Cites
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Decision Modelling For Health Economic Evaluation
Briggs, A., Claxton, K., & Sculpher, M. (2006) · doi:10.1093/oso/9780198526629.001.0001 · Cited by 3,153
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
An Introduction to Markov Modelling for Economic Evaluation
Briggs, A., & Sculpher, M. (1998) · PharmacoEconomics · doi:10.2165/00019053-199813040-00003 · Cited by 960
Health-related quality of life measured using the EQ-5D–5L: South Australian population norms
McCaffrey, N., Kaambwa, B., Currow, D. C., & Ratcliffe, J. (2016) · Health and Quality of Life Outcomes · doi:10.1186/s12955-016-0537-0 · Cited by 472
Comprehensive Profiling of Plasma Fatty Acid Concentrations in Young Healthy Canadian Adults
Abdelmagid, S. A., Clarke, S. E., Nielsen, D. E., Badawi, A., El-Sohemy, A., Mutch, D. M., & Ma, D. W. L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116195 · Cited by 360
Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Stein, E., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.05.031 · Cited by 342
Cited by
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
Marquina, C., Talic, S., Vargas-Torres, S. L., Petrova, M., Abushanab, D., Owen, A. J., Lybrand, S., Thomson, D., Liew, D., Zomer, E., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab001 · Cited by 78
Self-citationChapman, M. J., Zamorano, J. L., & Parhofer, K. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108172 · Cited by 67
Kam, N., Perera, K., Zomer, E., Liew, D., & Ademi, Z. (2020) · PharmacoEconomics · doi:10.1007/s40273-020-00948-w · Cited by 45
Self-citationMarquina, C., Lacaze, P. A., Tiller, J. M., Riaz, M., Sturm, A. C., Nelson, M. R., Ference, B. A., Pang, J., Watts, G. F., Nicholls, S. J., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab770 · Cited by 45
Self-citation
Metadata
- Authors
- Ademi, Z., Ofori-Asenso, R., Zomer, E., Owen, A., & Liew, D.
- Affiliations
- Monash University (AU)
- School of Public Health and Preventive Medicine, Monash University, Melbourne ,
- Corresponding author
- Ademi, Zanfina
- Venue
- European Journal of Preventive Cardiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-01-11
- Volume
- 28
- Issue
- 8
- Pages
- 897-904
- ISSN
- 2047-4873 (ISSN-L)
- 2047-4881
- OpenAlex
- W2998804962
- Semantic Scholar
- 053a9b58029cffca2ee189854a00d90ed52e2c8b
- Cited by
- 30
- References
- 35
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 6 · 2021: 7 · 2020: 8
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- European Journal of Preventive Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Keywords
- icosapent ethyl, omega-3 fatty acids, statins, combination therapy, cardiovascular disease prevention, cost-effectiveness, incremental cost-effectiveness ratio, quality-adjusted life years, primary prevention, secondary prevention, health care costs
- MeSH terms
- Australia, Cardiovascular Diseases, Cost-Benefit Analysis, Humans, Markov Chains, Risk Factors, Eicosapentaenoic Acid, Quality-Adjusted Life Years, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction. https://app.cochat.ai/papers/10.1177/2047487319896648
- The paper
- Ademi, Z., Ofori-Asenso, R., Zomer, E., Owen, A., & Liew, D. (2021). The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction. European Journal of Preventive Cardiology. https://doi.org/10.1177/2047487319896648
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.